Faeth Therapeutics, Inc. Sale and Leaseback Transaction, Gain (Loss), Net
Faeth Therapeutics, Inc. (FTH) had Sale and Leaseback Transaction, Gain (Loss), Net of $20.00 thousand as of 2021-04-20, per its 10-K filed 2023-03-29.
Discontinued › Income Statement › Other Income
us-gaap:SaleAndLeasebackTransactionGainLossNet · last filed 2023-03-29
- 2021-04-20: Sale and Leaseback Transaction, Gain (Loss), Net $20.00K.
| Period end | Sale and Leaseback Transaction, Gain (Loss), Net |
|---|---|
| 2021-04-20 | $20.00K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |